Health
STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.
- Published
- (1 h ago)
- Outlet
- STAT News
- Section
- Health
- Length here
- Headline and 15-word snippet. The full article is at the source.
More from STAT News and around the same time
What has actually caused the decline in drug overdose deaths?After years of steep increases, especially amid the pandemic, U.S. overdose deaths decreased 27% in 2024, and preliminary data from 2025 show another meaningful drop.Have you been impacted by Epic’s actions?STAT is looking to learn, from people with direct knowledge, how Epic's actions impact hospitals' technology choices. Share your story with us.Opinion: Freezing my eggs showed me just how anti-feminist the fertility industry can be“A few years ago, I froze my eggs — and the experience was anything but empowering,” writes physician Pooja Yerramilli.Opinion: How pediatricians like me are helping families stay calm and informed about measles“It is dizzying to have a family clamoring for the MMR vaccine in one room while the room next door adamantly opposes vaccination,” writes a pediatrician.STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technologyA STAT investigation found that Epic selectively withholds access to patient data, disadvantaging rival software developers and stymying innovation.STAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discountsMissouri AG told Lilly to stop forcing hospitals to provide claims data to receive discounted medicines under 340B, a sign more states are pushing back against drugmakers.This page holds the headline and a short snippet as published by STAT News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
